期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
重组人白介素-11(Ⅰ)与重组人促血小板生成素治疗化疗相关血小板减少的经济学评价 被引量:15
1
作者 陈芳君 张丹 +1 位作者 王增 林能明 《中国药师》 CAS 2015年第2期250-252,共3页
目的:评价重组人白介素-11(Ⅰ)[rhIL-11(Ⅰ)]和重组人促血小板生成素(rhTPO)治疗吉西他滨联合化疗相关血小板减少的效果和经济学意义。方法:采用回顾性分析法,收集2011年6月~2014年6月接受吉西他滨化疗导致血小板减少而使用rhIL... 目的:评价重组人白介素-11(Ⅰ)[rhIL-11(Ⅰ)]和重组人促血小板生成素(rhTPO)治疗吉西他滨联合化疗相关血小板减少的效果和经济学意义。方法:采用回顾性分析法,收集2011年6月~2014年6月接受吉西他滨化疗导致血小板减少而使用rhIL-11(Ⅰ)或rhTPO治疗的58例肺癌住院患者,比较两种升血小板药物的疗效,并做经济学评价。结果:rhIL-11(Ⅰ)组患者化疗后血小板最低值高于rh TPO组(P〈0.01);治疗后血小板持续减少时间短于rhTPO组(P〈0.01)。但两组血小板达标比例差异无统计学意义(P〉0.05)。采用最小成本分析,rhIL-11(Ⅰ)组平均成本低于rhTPO组(P〈0.01),rhIL-11(Ⅰ)组中不论接受GP、GC或其他以吉西他滨为基础的化疗方案,患者的平均成本均低于rhTPO组。结论:rh IL-11(Ⅰ)用于以吉西他滨为基础联合化疗治疗的肺癌患者后引起的血小板减少效果不劣于rhTPO,且在经济成本上具有一定优势。 展开更多
关键词 重组人白介素-11(Ⅰ) 重组人促血小板生成素 肺癌 吉西他滨 血小板减少 最小成本分析
在线阅读 下载PDF
Age,gender and type 2 diabetes contribute to the risk of gastric cancer:a retrospective single institution analysis 被引量:4
2
作者 王增 蔡鑫君 +2 位作者 刘孟娟 卢红阳 林能明 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2014年第11期799-803,共5页
Diabetes is involved in the development of several cancers. However, whether type 2 diabetes mellitus (T2DM) as well as other potential risk factors are related to gastric cancer (GC) remains unclear. In this stud... Diabetes is involved in the development of several cancers. However, whether type 2 diabetes mellitus (T2DM) as well as other potential risk factors are related to gastric cancer (GC) remains unclear. In this study, 1320 patients with gastric cancer (gastric cancer group) and 1252 thyroid nodule patients (control group), who were admitted in our hospital from Jan 2010 to Dec 2012, were analyzed in a case-control study. Logistic regression analysis was applied to evaluate the risk of diabetes condition, gender, age, body-mass index (BMI) level and other factors for GC. There were 416 patients with DM in the gastric cancer group (31.5%) and 120 patients with DM in the control group (9.6%). The differences between the two groups were significant (P = 0.000). Compared with the control group, the logistic regression analyses suggested that male patients had a higher risk of GC. Moreover, older individuals (especially over 65 years) were more susceptible to GC, and as for T2DM, it was found to be associated with GC, that is, the incidence in the gastric cancer group was significantly higher than in the control group. The OR values of age, T2DM, gender and BMI were 16.951, 15.130, 2.658 and 0.224, respectively. In conclusion, age, gender and T2DM are the risk factors of gastric cancer. Furthermore, male patient over 65 years with T2DM is susceptible to GC, and T2DM is the risk factor only second to age, and there might be synergistic effects among these factors. 展开更多
关键词 T2DM Age GENDER Gastric cancer Risk factor
原文传递
rhIL-11(Ⅰ)与rhIL-11在晚期肺癌化疗后血小板减少中的临床应用和经济学评价 被引量:2
3
作者 张丹 王增 +3 位作者 陈芳君 周晓芳 黄晓龙 林能明 《中国药房》 CAS CSCD 2014年第38期3556-3558,共3页
目的:评价升血小板药重组人白介素11(Ⅰ)[rhIL-11(Ⅰ)]、重组人白介素11(rhIL-11)用于肺癌化疗后血小板减少的疗效及经济学意义。方法:采用病例调查方法,回顾性分析53例接受吉西他滨为主的化疗并因此出现血小板减少的晚期肺癌住院患者... 目的:评价升血小板药重组人白介素11(Ⅰ)[rhIL-11(Ⅰ)]、重组人白介素11(rhIL-11)用于肺癌化疗后血小板减少的疗效及经济学意义。方法:采用病例调查方法,回顾性分析53例接受吉西他滨为主的化疗并因此出现血小板减少的晚期肺癌住院患者。其中使用rhIL-11(Ⅰ)治疗的患者23例(A组);使用rhIL-11治疗的患者30例,其中每日皮下注射rhIL-11 1.5 mg(B组,14例)或3 mg(C组,16例)。分析其相关临床信息,并评价2种升血小板药的疗效和用药经济性。结果:3组患者除年龄和病理类型外基本信息差异均无统计学意义。分层比较分析A组与C组患者临床信息表明,65岁以下、非腺癌(主要是鳞癌)的晚期肺癌患者使用rhIL-11(Ⅰ)的效果较好。与B组比较,A组治疗2 d后血小板计数与治疗后血小板最高值差异均有统计学意义(P<0.05);与C组比较,A组治疗2 d后血小板计数差异也有统计学意义(P<0.05)。结论:rhIL-11(Ⅰ)用于治疗肺癌患者化疗后引起的血小板减少效果相对较好,非腺癌(主要是鳞癌)的晚期肺癌患者可能是其优势人群。 展开更多
关键词 重组人白细胞介素-11(Ⅰ) 重组人白细胞介素-11 晚期肺癌 化疗 血小板减少 疗效 药物经济学
原文传递
Participation of clinical pharmacist specialized in oncology in the treatment of a patient with advanced esophageal carcinoma complicated with hypertension: one case report
4
作者 王增 丁海樱 +1 位作者 袁梅琴 林能明 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2014年第5期330-334,共5页
Clinical pharmacists specialized in oncology contributed to the safe and effective chemotherapy treatment for advanced esophageal carcinoma patients complicated with hypertension by participating in medication practic... Clinical pharmacists specialized in oncology contributed to the safe and effective chemotherapy treatment for advanced esophageal carcinoma patients complicated with hypertension by participating in medication practice. Optimal therapeutic regimen was proposed, and pharmaceutical care and health education were provided based on the condition of each patient. By providing pharmaceutical care for cancer patients with their pharmacy knowledge, clinical pharmacists specialized in oncology can not only reduce the potential risks of chemotherapy, but also take into account of other accompanying diseases, thus improving the comprehensive treatment of patients. Furthermore, it deepened the understanding of the role of clinical pharmacy practice by patients and other medical workers. Involvement of clinical pharmacist in therapeutic practice could improve the outcome of pharmacotherapy. 展开更多
关键词 Advanced esophageal cancer HYPERTENSION Clinical pharmacist CHEMOTHERAPY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部